NVIC

Janssen/Johnson & Johnson COVID-19 Vaccine and Guillain-Barré Syndrome (GBS)

Published November 10, 2021

On July 13, 2021, the FDA announced revisions to the Fact Sheet for Healthcare Providers administering the Janssen/Johnson & Johnson COVID-19 vaccine and the Fact Sheet for Recipients and Caregivers to include information regarding an increased risk of Guillain-Barré Syndrome (GBS) following vaccination. GBS, a serious neurological disorder where the body’s immune system attacks the peripheral nervous system, can cause muscle weakness, paralysis, and even death. According to the press release, the FDA reported 100 cases of GBS following vaccination, with 95 considered serious and requiring hospitalization, and one death. Government health officials noted that there was insufficient evidence to establish a causal relationship between the Johnson & Johnson/Janssen COVID-19 vaccine and GBS, and reported that “the known and potential benefits clearly outweigh the known and potential risks.” 

According to the CDC, rates of GBS following the Janssen/Johnson & Johnson COVID-19 vaccine were 21 times higher than after mRNA COVID-19 vaccines in the first 21 days post vaccination. After 42 days post vaccination, rates of GBS following the Janssen/Johnson & Johnson COVID-19 vaccine were 11 times higher.

Select disease / vaccine